Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC3 | O15379 | 4/20 | 0.57 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.57 |
| ▸ | HDAC2 | Q92769 | 4/20 | 0.57 |
| ▸ | NCOR2 | Q9Y618 | 2/20 | 0.57 |
| ▸ | LMNA | P02545 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | HTT | P42858 | 2/20 | 0.53 |
| ▸ | CA12 | O43570 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 2/20 | 0.53 |
| ▸ | CA2 | P00918 | 2/20 | 0.53 |
| ▸ | CA9 | Q16790 | 2/20 | 0.53 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.48 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.48 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16300489 | 0.90 | HDAC3 (0.60) | HDAC3HDAC1HDAC2NCOR2LMNA | |
| SCHEMBL27627546 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HTTHDAC8 | |
| SCHEMBL27949558 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HTTHDAC8 | |
| SCHEMBL27949557 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HTTHDAC8 | |
| SCHEMBL28283782 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HTTHDAC8 | |
| SCHEMBL27686370 | 0.88 | HDAC3 (0.54) | HDAC3HDAC1HDAC2HTTHDAC8 | |
| SCHEMBL7768532 | 0.86 | ALDH1A1 (0.56) | LMNASMN1; SMN2ALDH1A1HTTCA12 | |
| SCHEMBL733157 | 0.85 | LMNA (0.71) | LMNASMN1; SMN2ALDH1A1HTTCA12 | |
| SCHEMBL7405576 | 0.83 | HTT (0.65) | LMNASMN1; SMN2ALDH1A1HTTCA12 | |
| Hydrochloric Acid SCHEMBL27543692 | 0.83 | LMNA (0.69) | LMNASMN1; SMN2ALDH1A1HTTNPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | OCEAN UNIVERSITY OF CHINA (CN) | 2024-10-03 | — | — | US | disclosed |
| WO-2023011416-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | 中国海洋大学 | 2023-02-09 | — | — | WO | disclosed |
| US-20100104534-A1 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | SCHERING CORPORATION | 2010-04-29 | — | — | US | disclosed |
| US-20100104534-A1 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | SCHERING CORPORATION | 2010-04-29 | — | — | US | disclosed |
| WO-2008118332-A2 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | SCHERING CORPORATION (US) | 2008-10-02 | — | — | WO | disclosed |
| US-5389647-A | A prodrugs as hypotensive agents, treating congestive heart failure, urogenital disorders, vision defects | ABBOTT LABORATORIES (US) | 1995-02-14 | — | — | US | disclosed |
| US-5244910-A | Treating hypertension, congestive heart failure | ABBOTT LABORATORIES (US) | 1993-09-14 | — | — | US | disclosed |
| EP-0543936-A4 | RENIN INHIBITORS | — | 1993-06-30 | — | — | EP | disclosed |
| EP-0543936-A1 | RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1993-06-02 | — | — | EP | disclosed |
| WO-1992003429-A1 | RENIN INHIBITORS | ABBOTT LABORATORIES (US) | 1992-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240327418-A1 | MULTI-TARGET INHIBITOR TARGETING HDAC AND NAD SYNTHESIS AND USE OF MULTI-TARGET INHIBITOR | HDAC3, HDAC1, HDAC11 | HDAC3 1/4885HDAC1 2/4885HDAC2 4/4885 |
| US-20100104534-A1 | HYDRAZIDO-PEPTIDES AS INHIBITORS OF HCV NS3-PROTEASE | PREP, HPN, VIP | HDAC3 406/4885HDAC1 640/4885HDAC2 1115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.